Double-Blind 0.2mg CBP-307
CBP-307CN002
Phase 2 small_molecule completed
Quick answer
Double-Blind 0.2mg CBP-307 for Moderate to Severe Ulcerative Colitis is a Phase 2 program (small_molecule) at S.L with 1 ClinicalTrials.gov record(s).
Program details
- Company
- S.L
- Indication
- Moderate to Severe Ulcerative Colitis
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- completed